Key result
Integrating biopsy, autoantibodies, and advanced imaging facilitates personalized management of myocarditis.
Why the study?
Myocarditis represents a challenging diagnosis with variable clinical presentation, unpredictable course, and lack of established causative treatment, despite increasing incidence and expanding non-invasive diagnostic methods.
This review provides updated diagnostic and therapeutic algorithms for the personalized management of myocarditis and inflammatory cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Should not yet change myocarditis practice; leaves open prospective validation of personalized biopsy and imaging strategies.
Myocarditis is an inflammatory heart disease induced by infectious and non-infectious causes frequently triggering immune-mediated pathologic mechanisms leading to myocardial damage and dysfunction. In approximately half of the patients, acute myocarditis resolves spontaneously while in the remaining cases, it may evolve into serious complications including inflammatory cardiomyopathy, arrhythmias, death, or heart transplantation. Due to the large variability in clinical presentation, unpredictable course of the disease, and lack of established causative treatment, myocarditis represents a challenging diagnosis in modern cardiology. Moreover, an increase in the incidence of myocarditis and inflammatory cardiomyopathy has been observed in recent years. However, there is a growing potential of available non-invasive diagnostic methods (biomarkers, serum anti-heart autoantibodies (AHA), microRNAs, speckle tracking echocardiography, cardiac magnetic resonance T1 and T2 tissue mapping, positron emission tomography), which may refine the diagnostic workup and/or noninvasive follow-up. Personalized management should include the use of endomyocardial biopsy and AHA, which may allow the etiopathogenetic subsets of myocarditis (infectious, non-infectious, and/or immune-mediated) to be distinguished and implementation of disease-specific therapies. In this review, we summarize current knowledge on myocarditis and inflammatory cardiomyopathy, and outline some practical diagnostic, therapeutic, and follow-up algorithms to facilitate comprehensive individualized management of these patients.
No takes yet. Share an insight, caveat, or question.
Tymińska et al. (2022) conducted a review in Myocarditis and Inflammatory Cardiomyopathy. Personalized management (endomyocardial biopsy, anti-heart autoantibodies, non-invasive imaging) was evaluated. Personalized management incorporating endomyocardial biopsy, anti-heart autoantibodies, and advanced non-invasive imaging facilitates comprehensive individualized treatment of myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: